Zhengshi Lin

机构：First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University · ORCID：0009-0005-5964-0760

发表论文 43 篇 · 总被引 1251 次 · h-index 18

代表论文

• Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial (2023 · EClinicalMedicine · 被引 48)
• Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial (2024 · The Lancet Infectious Diseases · 被引 33)
• Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus (2023 · Med · 被引 24)
• Epidemiology of HBoV1 infection and relationship with meteorological conditions in hospitalized pediatric patients with acute respiratory illness: a 7-year study in a subtropical region (2018 · BMC Infectious Diseases · 被引 24)
• Different Circulation Pattern of Multiple Respiratory Viruses in Southern China During the COVID-19 Pandemic (2022 · Frontiers in Microbiology · 被引 22)
• Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 18)